News / Taiwan / cnyes
PharmaEssentia's Ropeg Receives Japanese Approval for All ET Patients
Health Technology · Pharmaceuticals: Major · cnyes · 2026-08-24
6446
PharmaEssentia has secured Japanese regulatory approval for its drug Ropeg to treat all patients with essential thrombocythemia, marking a significant milestone.
What Happened
Regulatory Milestone: PharmaEssentia announced that its drug, Ropeg, has been approved by Japan's Ministry of Health, Labour and Welfare for the treatment of essential thrombocythemia (ET). This approval covers all ET patients, marking a significant expansion of the drug's therapeutic reach in the region.
Clinical Foundation: The approval is supported by robust data from the global Phase 3 SURPASS-ET trial and the North American EXCEED-ET study. Unlike previous approvals that were limited to specific patient subsets, the Japanese authorization allows for the treatment of both treatment-naive and previously treated patients.
Market Strategy: The company is working closely with local medical teams to accelerate the adoption of Ropeg within the Japanese myeloproliferative neoplasm (MPN) market. Management is focused on ensuring a smooth commercial rollout to maximize the drug's impact.
U.S. Outlook: Regarding the U.S. market, the FDA has set a PDUFA date of August 30. PharmaEssentia has already mobilized its U.S. sales and marketing teams to ensure immediate commercialization efforts upon potential approval, aiming for rapid market penetration.
Read original
More in Health Technology
Health Technology · cnyes · 2026-08-24
Biotech firm JieLiKang (7686) is set to list on the emerging stock market on August 31, leveraging its proprietary LipoShell and HeliBarb platforms to capture growth in breast reconstruction and medical aesthetics.
7686
Health Technology · economic_daily · 2026-08-24
QIC CEO Felix Li suggests that as AI and semiconductor valuations peak, capital rotation into Taiwan's resilient biotech sector could trigger exponential market cap growth.
6446, 6712, 6841, 6891, 7850
Health Technology · yonhap_finance · 2026-08-24
South Korean pharmaceutical and biotech firms are on track to surpass last year's record in technology exports, fueled by a series of major global deals.
128940, 196170, 226950, 950220
Latest in Taiwan
Finance · cnyes · 2026-08-24
Starting December 7, 2026, fractional share trading in Taiwan will synchronize with the main market opening at 9:00 AM, featuring new pre-market price discovery.
Electronic Technology · cnyes · 2026-08-24
CipherLab is entering a new growth phase with the launch of its AI Core 2.0 platform, new Wi-Fi 7 industrial mobile computers, and expanded software services.
6160
Finance · economic_daily · 2026-08-24
Starting December 7, Taiwan's fractional share trading will align its opening time with the main board at 9:00 AM, featuring new pre-market price discovery tools.
Commercial Services · economic_daily · 2026-08-24
The Taiwan Stock Exchange has scheduled investor conferences for 17 listed companies in September, including Shihlin Electric and CPDC, to enhance transparency.
1215, 1219, 1314, 1419, 1456, 1503, 1604, 1702, 2032, 2493, 2608, 2851, 4557, 4739, 6136, 8201, 9926